Skip to main content

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

--News Direct--

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/incannex-readying-for-phase-2-clinical-trial-of-anti-inflammatory-drug-ihl-675a-480207835

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.88
+4.41 (2.03%)
AAPL  262.95
+0.71 (0.27%)
AMD  235.55
-5.01 (-2.08%)
BAC  52.17
+0.13 (0.26%)
GOOG  252.90
-4.12 (-1.60%)
META  731.80
-0.37 (-0.05%)
MSFT  515.27
-1.51 (-0.29%)
NVDA  180.76
-1.88 (-1.03%)
ORCL  278.10
+0.92 (0.33%)
TSLA  444.38
-3.05 (-0.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.